These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37384899)

  • 21. Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position.
    Bertucci V; Green JB; Fezza JP; Brown J; Gallagher CJ; Solish N
    Aesthet Surg J; 2023 Nov; 43(Suppl 1):S10-S18. PubMed ID: 36322141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study.
    Bertucci V; Humphrey S; Carruthers J; Solish N; Muhn C; Swift A; Rubio RG; Shears G; Rosen N
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S262-S273. PubMed ID: 33065952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
    Grimes PE; Shabazz D
    Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study.
    Molina B; Grangier Y; Mole B; Ribe N; Martín Diaz L; Prager W; Paliargues F; Kerrouche N
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1382-8. PubMed ID: 25495499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.
    Frampton JE; Easthope SE
    Am J Clin Dermatol; 2003; 4(10):709-25. PubMed ID: 14507232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles.
    Michaels BM; Csank GA; Ryb GE; Eko FN; Rubin A
    Aesthet Surg J; 2012 Jan; 32(1):96-102. PubMed ID: 22231417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
    Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
    J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles.
    Carruthers A; Carruthers J; Fagien S; Lei X; Kolodziejczyk J; Brin MF
    Dermatol Surg; 2016 Sep; 42(9):1094-101. PubMed ID: 27427996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
    Monheit GD; Baumann L; Maas C; Rand R; Down R
    Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications of Cosmetic Botulinum Toxin A Injections to the Upper Face: A Systematic Review and Meta-Analysis.
    Zargaran D; Zoller F; Zargaran A; Rahman E; Woollard A; Weyrich T; Mosahebi A
    Aesthet Surg J; 2022 Apr; 42(5):NP327-NP336. PubMed ID: 35178552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined use of botulinum toxin type A and B for forehead rhytides: a randomized, double-blind, split-face study.
    Choi JW; Youn CS; An HT; Yoo JY; Na JI; Park KC; Youn SW; Huh CH
    J Dermatolog Treat; 2013 Apr; 24(2):126-32. PubMed ID: 21801115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data.
    Schlessinger J; Friedmann DP; Mayoral F; Mraz Robinson D; Glaser D; Wu D; Marcus K; Somenek M; Lin X
    J Drugs Dermatol; 2021 Sep; 20(9):988-995. PubMed ID: 34491022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
    Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
    Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial.
    Fagien S; Avelar RL; Cox SE; Joseph JH; Kaufman-Janette J; Marcus KA
    Aesthet Surg J; 2024 Aug; 44(9):987-1000. PubMed ID: 38506148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.